- Home
- DLB vs MDGL Comparison
DLB vs MDGL Comparison
Compare DLB & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLB
- MDGL
- Stock Information
- Founded
- DLB 1965
- MDGL 2011
- Country
- DLB United States
- MDGL United States
- Employees
- DLB N/A
- MDGL N/A
- Industry
- DLB Multi-Sector Companies
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- DLB Miscellaneous
- MDGL Health Care
- Exchange
- DLB Nasdaq
- MDGL Nasdaq
- Market Cap
- DLB 7.4B
- MDGL 6.1B
- IPO Year
- DLB 2005
- MDGL N/A
- Fundamental
- Price
- DLB $76.37
- MDGL $298.40
- Analyst Decision
- DLB Strong Buy
- MDGL Strong Buy
- Analyst Count
- DLB 4
- MDGL 9
- Target Price
- DLB $101.75
- MDGL $420.63
- AVG Volume (30 Days)
- DLB 312.2K
- MDGL 360.9K
- Earning Date
- DLB 07-31-2025
- MDGL 08-05-2025
- Dividend Yield
- DLB 1.73%
- MDGL N/A
- EPS Growth
- DLB 36.08
- MDGL N/A
- EPS
- DLB 2.64
- MDGL N/A
- Revenue
- DLB $1,320,184,000.00
- MDGL $317,383,000.00
- Revenue This Year
- DLB $6.38
- MDGL $286.17
- Revenue Next Year
- DLB $4.65
- MDGL $64.17
- P/E Ratio
- DLB $28.91
- MDGL N/A
- Revenue Growth
- DLB 4.03
- MDGL N/A
- 52 Week Low
- DLB $66.35
- MDGL $200.63
- 52 Week High
- DLB $89.66
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- DLB 56.55
- MDGL 45.49
- Support Level
- DLB $74.08
- MDGL $307.43
- Resistance Level
- DLB $77.00
- MDGL $357.91
- Average True Range (ATR)
- DLB 0.93
- MDGL 14.09
- MACD
- DLB 0.16
- MDGL -2.88
- Stochastic Oscillator
- DLB 78.42
- MDGL 18.38
About DLB Dolby Laboratories
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company designs and manufactures audio, imaging, accessibility, and other hardware and software solutions for the cinema, with occasional applications in the television, broadcast, and live entertainment industries. The company operates in the United States and internationally.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.